[go: up one dir, main page]

AR102092A1 - Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii) - Google Patents

Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii)

Info

Publication number
AR102092A1
AR102092A1 ARP150103098A ARP150103098A AR102092A1 AR 102092 A1 AR102092 A1 AR 102092A1 AR P150103098 A ARP150103098 A AR P150103098A AR P150103098 A ARP150103098 A AR P150103098A AR 102092 A1 AR102092 A1 AR 102092A1
Authority
AR
Argentina
Prior art keywords
polypeptide
seq
detailed
antibody
substance
Prior art date
Application number
ARP150103098A
Other languages
English (en)
Inventor
Suzuki Tsukasa
Kitazawa Takehisa
Muto Atsushi
Igawa Tomoyuki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR102092A1 publication Critical patent/AR102092A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Un anticuerpo caracterizado porque neutraliza una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación VIII. Reivindicación 3: El anticuerpo de acuerdo con la reivindicación 1 ó 2, caracterizado porque el anticuerpo biespecífico toma la forma de cualquiera de los anticuerpos que se describen más adelante, que comprenden un primer polipéptido asociado a un tercer polipéptido y un segundo polipéptido asociado a un cuarto polipéptido: un anticuerpo biespecífico en el cual el primer polipéptido es una cadena H que consiste en una secuencia de aminoácidos como la que se detalla en SEQ ID Nº 9, el segundo polipéptido es una cadena H que consiste en una secuencia de aminoácidos como la que se detalla en SEQ ID Nº 11 y el tercer polipéptido y el cuarto polipéptido son cadenas L comunes como la que se detalla en SEQ ID Nº 10 (Q499-z121 / J327-Z119 / L404-k); o un anticuerpo biespecífico en el cual el primer polipéptido es una cadena H que consiste en una secuencia de aminoácidos como la que se detalla en SEQ ID Nº 36, el segundo polipéptido es una cadena H que consiste en una secuencia de aminoácidos como la que se detalla en SEQ ID Nº 37 y el tercer polipéptido y el cuarto polipéptido son cadenas L comunes como la que se detalla en SEQ ID Nº 38 (Q153-G4K / J142-G4H / L180-K). Reivindicación 8: Un ácido nucleico caracterizado porque codifica un anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 7. Reivindicación 9: Un vector caracterizado porque en él se ha insertado un ácido nucleico de acuerdo con la reivindicación 8. Reivindicación 10: Una célula caracterizada porque comprende un ácido nucleico de acuerdo con la reivindicación 8 o un vector de acuerdo con la reivindicación 9. Reivindicación 11: Un método para producir un anticuerpo, caracterizado porque comprende cultivar una célula de acuerdo con la reivindicación 10.
ARP150103098A 2014-09-26 2015-09-25 Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii) AR102092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014197207 2014-09-26

Publications (1)

Publication Number Publication Date
AR102092A1 true AR102092A1 (es) 2017-02-01

Family

ID=55581180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103098A AR102092A1 (es) 2014-09-26 2015-09-25 Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii)

Country Status (17)

Country Link
US (1) US11214623B2 (es)
EP (1) EP3199554A4 (es)
JP (2) JP6702877B2 (es)
KR (1) KR102517509B1 (es)
CN (1) CN107108746B (es)
AR (1) AR102092A1 (es)
AU (1) AU2015322662B2 (es)
CA (1) CA2961968C (es)
IL (1) IL251111B (es)
MX (1) MX388728B (es)
MY (1) MY192018A (es)
NZ (1) NZ730611A (es)
RU (1) RU2737145C2 (es)
SG (1) SG11201702259RA (es)
TW (1) TWI700300B (es)
WO (1) WO2016047656A1 (es)
ZA (1) ZA201701844B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
NZ746002A (en) 2016-04-28 2025-08-29 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
WO2018181870A1 (ja) * 2017-03-31 2018-10-04 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN107449925A (zh) * 2017-09-22 2017-12-08 郑州大学第附属医院 一种用于凝血因子viii抑制物检测的缓冲液以及检测方法
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
EP3830135A1 (en) * 2018-08-01 2021-06-09 Novo Nordisk A/S Improved procoagulant antibodies
JP7530362B2 (ja) 2018-12-21 2024-08-07 カイマブ・リミテッド 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体
IL285026B2 (en) 2019-01-22 2025-07-01 Univ Clemson Res Foundation Anti-elastin antibodies and methods of use
EP4155405A4 (en) * 2020-05-22 2024-07-03 Chugai Seiyaku Kabushiki Kaisha Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0432134A1 (en) 1984-01-12 1991-06-12 Chiron Corporation Hybridoma cell lines and monoclonal antibodies
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0332287A (ja) 1989-06-29 1991-02-12 Pioneer Electron Corp 記録媒体演奏装置
EP0505357B1 (en) 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
TW212184B (es) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
JPH06104071A (ja) 1991-08-30 1994-04-15 Jasco Corp 発熱体セラミックス溶接加工方法
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU7214294A (en) 1993-07-01 1995-01-24 Dade International Inc. Process for the preparation of factor x depleted plasma
WO1996001653A1 (en) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5755446A (en) 1996-12-24 1998-05-26 United Technologies Corporation Seal apparatus between a shaft and a non-linear inner surface of a housing
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CN1073412C (zh) 1998-03-19 2001-10-24 中国科学院化学研究所 一种高分子微包囊的制备方法
EP1074842A1 (en) 1999-07-21 2001-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Catalytic anti-factor VIII allo-antibodies
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU2001271066A1 (en) 2000-07-17 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method for screening ligand having biological activity
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
AU2003235833A1 (en) 2002-04-26 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Method of screening agonistic antibody
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
EP1605058B1 (en) 2003-01-21 2009-05-13 Chugai Seiyaku Kabushiki Kaisha Method of screening light chain of antibody light chains
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
EP1915176A4 (en) 2005-07-15 2008-12-03 Univ Vermont HIGHLY SENSITIVE IMMUNASSAYS AND ANTIBODIES FOR THE DETECTION OF BLOOD FACTOR VIII
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
IL226291A (en) * 2006-09-08 2016-05-31 Abbvie Bahamas Ltd A binding protein that links interleukin-13, its pharmaceutical composition and its use in the preparation of a drug.
KR20100065158A (ko) 2007-08-23 2010-06-15 엘에프비 바이오테크놀로지스 인자 ⅷ의 ｃ1 도메인에 대향하는 저해 항체의 저해 활성을 중화시키는 항-개별특이형의 항체들
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP2011509650A (ja) * 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
FR2933496B1 (fr) 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CN101906160A (zh) 2009-06-05 2010-12-08 苏州泽璟生物制药有限公司 一种抗人凝血因子ⅷ单克隆抗体及其制备方法和用途
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
KR102380315B1 (ko) 2009-12-25 2022-03-29 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
AU2011274423B2 (en) * 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
AU2013229613B2 (en) 2012-03-08 2015-07-30 F. Hoffmann-La Roche Ag Abeta antibody formulation
PL2902787T3 (pl) * 2012-09-28 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Sposób oceny reakcji krzepnięcia krwi
JP2016515538A (ja) * 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
AU2016245887B2 (en) 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN107454906B (zh) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
NZ746002A (en) 2016-04-28 2025-08-29 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
WO2018181870A1 (ja) 2017-03-31 2018-10-04 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型

Also Published As

Publication number Publication date
CN107108746A (zh) 2017-08-29
KR102517509B1 (ko) 2023-04-04
JP6702877B2 (ja) 2020-06-03
TWI700300B (zh) 2020-08-01
CA2961968A1 (en) 2016-03-31
SG11201702259RA (en) 2017-04-27
IL251111B (en) 2021-03-25
ZA201701844B (en) 2021-10-27
AU2015322662B2 (en) 2020-12-10
US11214623B2 (en) 2022-01-04
WO2016047656A1 (ja) 2016-03-31
RU2737145C2 (ru) 2020-11-25
RU2017113732A3 (es) 2019-01-30
JP2020108395A (ja) 2020-07-16
AU2015322662A1 (en) 2017-04-06
KR20170064539A (ko) 2017-06-09
EP3199554A4 (en) 2018-07-18
EP3199554A1 (en) 2017-08-02
US20170275376A1 (en) 2017-09-28
MX2017003693A (es) 2017-06-26
MY192018A (en) 2022-07-22
JPWO2016047656A1 (ja) 2017-07-13
MX388728B (es) 2025-03-20
TW201619201A (zh) 2016-06-01
IL251111A0 (en) 2017-04-30
CN107108746B (zh) 2021-06-08
BR112017005801A2 (pt) 2017-12-19
RU2017113732A (ru) 2018-10-23
NZ730611A (en) 2021-12-24
CA2961968C (en) 2023-01-24

Similar Documents

Publication Publication Date Title
AR102092A1 (es) Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii)
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX2025010485A (es) Composiciones de vcar y metodos de uso
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX360707B (es) Receptor antigénico quimérico.
PE20170286A1 (es) Diacuerpos heterodimericos biespecificos y sus usos
MX2020004229A (es) Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
CR20240116A (es) RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518)
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2017000510A2 (es) Constructos de car
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
CL2017001369A1 (es) Proceso para manipular el nivel del contenido de glicano de una glicoproteina
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX375524B (es) Anticuerpos anti-axl.
MX2016010285A (es) Ingenieria genetica multiplexada habilitada por crispr.
MX2016013144A (es) Metodo y composiciones para inmunoterapia celular.
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
AR124933A2 (es) Molécula de ácido nucleico aislada, vector aislado y célula cho aislada y modificada que es incapaz de regenerar en un individuo completo